tirzepatide surmount 1 SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 π πSustained weight loss of 22.9% or an average 54lbs over 3 years π½94% reduction in risk of progression to diabetes. Number surmount-1 trial tirzepatide non-diabetic obesity
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 23 - Sep 28












:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)














